Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
The survey indicates that 30% of people are still feeling depressed or hopeless on a few days as against GOQii’s last year survey on mental Health where 43% of Indians were depressed
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Routine tests undertaken by women dropped by 35% in 2020
Company expects strong organic growth in sales, EBITDA in 2022
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The company has reported total income of Rs. 3715.8 crores during the quarter ended December 31, 2021
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
Topline results from the randomized EMPATHY Part A study in acute Covid-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic candidate vs. placebo, met the primary endpoint of viral load reduction over eight days
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
Subscribe To Our Newsletter & Stay Updated
